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ABSTRACT
Objective: Human papillomavirus (HPV) testing is widely incorporated into cervical cancer 
screening strategies. Current screening requires pelvic examination for cervical sampling, 
which may compromise participation. The acceptance could be raised by introducing testing 
on vaginal swabs. We explored the interchangeability of vaginal swabs and cervical smears 
for HPV testing, by means of a prospective study conducted in female sex workers (FSWs). 
Besides, we report on the occurrence of 32 different HPV genotypes in FSW with low-grade 
squamous intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL).
Methods: Paired physician-collected vaginal swabs and cervical smears from 303 FSW were 
tested for HPV using the Abbott RealTime High-Risk HPV assay. Cervical cytology was 
examined on cervical smears. In case of HSIL/LSIL cytological classification (n=52), both 
samples were genotyped using INNO-LiPa HPV Genotyping Extra II.
Results: The overall prevalence of high-risk (HR)-HPV was 51%. In FSW with HSIL/LSIL 
cervical cytology, the sensitivity and specificity of vaginal samples for the detection of HR-
HPV was 100% and 70% and for probable HR-HPV 100% and 91%. The mean number of 
genotypes identified in vaginal samples (mean=3.5; 95% confidence interval [CI]=2.8–4.2) 
was significantly higher than in cervical smear samples (mean=2.6; 95% CI=2.1–3.0) 
(p=0.001). The most frequently encountered HR-HPV genotypes were HPV16, 31, 51, and 52.
Conclusion: As our study shows that vaginal swabs are equivalent to cervical smears for 
the detection of (probable) HR-HPV, vaginal swabs can be used for HPV testing in cervical 
cancer screening strategies. Given the acceptance of vaginal sampling, this finding offers an 
opportunity to boost screening coverage.
Keywords: Neisseria Gonorrhoeae; Chlamydia Trachomatis; Papillomaviridae;  
Trichomonas Vaginalis; Mycoplasma Genitalium; Sexually Transmitted Diseases
INTRODUCTION
Although the vast majority of human papillomavirus (HPV) genotypes causes benign warts 
of the skin or genital region, infection by some HPV genotypes can lead to the development 
of malignancy, mainly cervical cancer. Besides, 43% of vulvar and 70% of vaginal cancers are 
attributable to HPV [1]. Fifteen HPV types are considered carcinogenic or high-risk (HR): 16, 
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18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82. Three other HPV types are considered 
probably carcinogenic or probably high-risk (pHR): 26, 53, and 66. Twelve HPV types are 
classified as low-risk (LR) types: 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108 [2]. 
Elucidation of the role of HPV in cervical cancer pathogenesis has led to the incorporation 
of HPV testing into (primary) screening strategies. Several strategies have been suggested 
for early detection of cervical cancer, using cervical cytology and/or molecular tests for HPV 
detection in cervical smears. The current Belgian screening program is cytology-based, with 
molecular detection of oncogenic HPV only in case of atypical squamous cells of undetermined 
significance (ASC-US) or follow-up samples of women previously treated for high-grade 
lesions. In contrast, co-testing (simultaneous HPV testing and cervical cytology) has become 
the predominant method of screening for instance in the United States and HPV testing is 
introduced as the primary screening test in organized screening programs for instance in 
The Netherlands [3]. Whilst cytology-based screening programs rely on clinician-collected 
cervical samples, vaginal (self-) collection is likely to become an integral part of screening, 
as HPV testing gradually gains ground. This is because the success of screening depends 
highly on the participation of the target population, and screening programs requiring pelvic 
examination may pose a barrier. Indeed, women who are not or infrequently screened are 
known to be at highest risk of developing cervical cancer [3]. Incorporation of non-invasive 
(self-) sampling methods, e.g., vaginal sampling, might increase the acceptance of testing 
and optimize screening coverage. However, the clinical validity of vaginal swabs has not yet 
been well established. The presented work explores the interchangeability of vaginal swabs 
and cervical smears for HPV testing, by means of a prospective study conducted in 303 female 
sex workers (FSWs) in Belgium. Furthermore, we report on the occurrence of 32 different HPV 
genotypes in paired vaginal swabs and cervical smears from 54 FSWs with low-grade squamous 
intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL).
MATERIALS AND METHODS
The study was approved by the Ethical Committee of the Ghent University Hospital with 
Belgian registration number, B670201524867.
The study was conducted in 303 FSWs embedded in a health program for sex workers in 
Flanders (Pasop vzw, Ghent, Belgium), between June 2015 and June 2016. Pasop vzw was 
founded in 1990 and provides sex work specific occupational health services focused on 
prevention and outreach, complementary to existing care. The Pasop vzw team consists of 2 
general health practitioners, assisted by nurses and social workers. Pasop vzw offers sexually 
transmitted infection (STI) screening, vaccination against hepatitis B, contraceptive counseling, 
sex education, and psychological assistance. STI screening is indicated at first contact 
between the Pasop vzw team and the sex worker, as well as after perceived risk (e.g., condom 
failure) or when signs or symptoms of STI are present. Women eligible for STI screening were 
consecutively informed on our study by a physician and invited to participate, after documenting 
the informed consent. The studied population does not lend itself for longitudinal follow-up, 
as it consists of anonymized individuals who switch workplace and residence on a regular basis. 
Therefore, FSW were included consecutively during the selected time frame.
A vaginal Abbott swab (VA) (Abbott Laboratories, Abbott Park, IL, USA) and a ThinPrep 
cervical smear (CS) (Hologic Inc., Bedford, MA, USA) were sampled consecutively by a 
physician. Vaginal swabs, sampled halfway the vagina, were taken prior to the cervical 
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samples, in order to avoid potential dilution by the lubricant used during pelvic examination 
[4,5]. All samples were sent to the Department of Laboratory Medicine of the Ghent 
University Hospital at room temperature within a 24-hour timeframe. Immediately after 
arrival, the VA samples were stored at −20°C and tested for HPV within 1 week, using 600 
µL of sample for Abbott RealTime High Risk HPV assay on the Abbott m2000sp/rt systems 
(Abbott Laboratories). This test is intended to detect 14 HR-HPV genotypes (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66, and 68) and to partially genotype 16 and 18 from the other HR 
genotypes. Each signal is either determined as “Detected” if the cycle number (CN) is less 
than a fixed assay cutoff cycle or is determined as “Not Detected” if the CN is not generated 
or if the CN is greater than or equal to the assay cutoff cycle, which applies only to cervical 
smears. The package insert mentions that the assay tracks HPV genotypes at a variable limit 
of detection: 5,000 copies/mL for HPV 16, 18, 35, 39, 45, 51, 59, 66, and 68; 20,000 copies/mL 
for HPV 31, 33, 52, and 56; and 50,000 copies/mL for HPV 58.
The CS samples were first subjected to cervical cytology investigation at the Department 
of Pathology of the Ghent University Hospital, using the Bethesda system: negative for 
intraepithelial lesions or malignancy (NILM); ASC-US; LSIL or HSIL. All smears were screened 
by a cytologist and supervised by a pathologist in case of any suspected abnormality. In case of 
HSIL, second reading by senior pathologist was performed. Afterwards, samples were sent to 
the Department of Laboratory Medicine and stored at −20°C, prior to HPV testing.
In case of LSIL or HSIL abnormity, both VA and CS samples were genotyped using INNO-
LiPa HPV Genotyping Extra II (Fujirebio, Ghent, Belgium) following the manufacturer's 
instructions. This process consist of a multiplex polymerase chain reaction (PCR)-based 
assay targeting the HPV L1 gene, starting from the DNA extracts generated by the Abbott 
m2000sp system (Abbott Laboratories), followed by reversed line blot hybridization using 
the Autoblot 3000H tray (Fujirebio). The assay detects 32 different HPV genotypes: 13 HR-
HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68); 6 pHR-HPV genotypes 
(26, 53, 66, 70, 73, and 82); 9 LR-HPV genotypes (6, 11, 40, 42, 43, 44, 54, 61, and 81) and 
4 genotypes with unknown significance (unknown risk [UR]-HPV]) (62, 67, 83, and 89). 
All tests were read manually by 2 independent readers. In case of disagreement, the results 
were read by a third reader. The INNO-LiPa results were compared between paired VA and 
CS samples in order to assess the usefulness of vaginal samples for HPV testing. Besides, 
the results of INNO-LiPa were compared with the results of Abbott, allowing analysis of 
the importance of the pHR-HPV genotypes not included in the Abbott assay. Results were 
analyzed statistically using MedCalc software v15.6.1 (MedCalc Software, Mariakerke, 
Belgium). The difference in prevalence between paired samples was calculated using the 
McNemar test. The level of agreement between paired samples for each HPV genotype 
and for each HPV risk group was calculated using the kappa inter rater agreement (<0.20, 
poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, 
good agreement; and >0.81, very good agreement) [6]. The difference in mean number of 
genotypes in paired samples was calculated using the paired samples t-test.
RESULTS
Within the selected time frame, 303 FSWs participated. The results from 11/303 FSWs were 
excluded because the vaginal sample contained inadequate volume. The baseline prevalence 
for HR-HPV was calculated by categorizing each FSW as infected when at least 1 out of 2 
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samples was positive for the Abbott HR-HPV test. Fifteen FSWs were included twice, of which 
8 tested positive on both occasions with intervals of 1 to 7 months. Given the persistent 
nature of HPV infections, all duplicates were calculated as one episode, resulting in a 
prevalence rate for HR-HPV of 51% (144/284).
Overall, cervical cytology showed 56% NILM, 26% ASC-US, 12% LSIL, and 6% HSIL. In case 
of HSIL or LSIL, there was a preponderance of HR-HPV positivity, as shown in Fig. 1. One FSW 
with HSIL cervical cytology had a negative result on Abbott HR-HPV testing. Genotyping using 
INNO-LiPa, however, revealed the presence of HPV 67. This genotype is considered to be of UR, 
but is gaining interest as it appears to be more prevalent in vaccinated women [7].
Comparison of the Abbott HR-HPV results on paired VA/CS samples revealed that HR-HPV 
was detected more frequently in vaginal swabs (137/284 [48.2%]) than in cervical smears 
(118/284 [41.5%]) (p=0.005). This finding necessitated further genotyping by INNO-LiPa, 
in order to thoroughly compare the occurrence of different HPV genotypes, rather than to 
compare only the presence or absence of HR-HPV. For this analysis, we made a sub-selection 
of the 54 FSWs with HSIL or LSIL cervical cytology results, because those groups have the 
highest clinical relevance and showed preponderance of HR-HPV positivity (Fig. 1). In this 
subpopulation, 2/54 FSWs were excluded due to sample shortage, leaving 104 samples from 
52 FSWs to be processed. Analysis of the occurrence of the 32 different HPV genotypes 
included in the INNO-LiPa assay revealed an overall prevalence of 98% (51/52) for any HPV 
genotype; 87% (45/52) for HR-HPV; 44% (23/52) for pHR-HPV; 54% (28/52) for LR-HPV; and 
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NILM
n=168
HR-HPV+
n=53
HR-HPV−
n=115
ASC-US
n=78
Cervical cytology and HPV DNA
n=300
Eligible FSW
n=303
Exclusion (sample shortage)
n=3
HPV genotyping
n=52
Exclusion (sample shortage)
n=2
HR-HPV+
n=31
HR-HPV−
n=47
LSIL*,†
n=35
HR-HPV+
n=25
HR-HPV−
n=10
HSIL‡,§
n=19
HR-HPV+
n=18
HR-HPV−
n=1
Fig. 1. Flowchart of inclusion of FSWs and number of positive results for HR-HPV on CS in function of the result of cervical cytology. 
ASC-US, atypical squamous cells of undetermined significance; CS, ThinPrep cervical smear; FSW, female sex worker; HPV, human papillomavirus; HR, high-risk; 
HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesions or malignancy; +, 
positive; −, negative. 
*Significantly higher positivity rate than NILM (p=0.001); †Significantly higher positivity rate than ASC-US (p<0.001); ‡Significantly higher positivity rate than NILM 
(p=0.019); §Significantly higher positivity rate than ASC-US (p=0.001).
33% (17/52) for UR-HPV (Table 1). The 1 FSW with a fully negative genotyping analysis had 
LSIL cervical cytology. The difference in prevalence between paired samples was significant 
only for UR-HPV: 31% (16/52) in VA compared to 17% (9/52) in CS (p=0.040).
As the main purpose of our study was to investigate the interchangeability of vaginal 
swabs and cervical smears for HPV testing, we calculated the sensitivity and specificity for 
vaginal swabs, using the results on cervical smears as the gold standard. The sensitivity and 
specificity were 100% and 70% for the detection of HR-HPV; 100% and 91% for pHR-HPV; 
75% and 67% for LR-HPV; and 89% and 81% for UR-HPV.
Table 1 shows the level of agreement (kappa) between paired samples for each genotype and 
for each risk group [6]. Complete agreement between paired samples was achieved in only 
27% of cases for all HPV genotypes; in 60% of cases for all HR-HPV genotypes; in 88% of 
cases for all pHR-HPV genotypes; in 60% of cases for all LR-HPV genotypes and in 83% of 
cases for all UR-HPV genotypes.
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Table 1. HPV types identified in paired VA and CS samples collected from 52 FSWs
Type VA+/CS− VA−/CS+ VA+/CS+ VA−/CS− Kappa (95% CI)
Any HPV 0 3 48 1 0.38 (−0.15 to 0.92)
Any HR 3 0 42 7 0.79 (0.57 to 1.00)
HPV 16 1 0 18 33 0.96 (0.87 to 1.00)
HPV 18 3 0 2 47 0.55 (0.10 to 0.99)
HPV 31 3 2 7 40 0.68 (0.41 to 0.91)
HPV 33 0 2 3 47 0.73 (0.38 to 1.00)
HPV 35 2 0 4 46 0.78 (0.49 to 1.00)
HPV 39 0 1 5 46 0.90 (0.70 to 1.00)
HPV 45 1 0 4 47 0.88 (0.64 to 1.00)
HPV 51 5 1 6 40 0.60 (0.32 to 0.88)
HPV 52 3 1 8 40 0.75 (0.52 to 0.98)
HPV 56 1 0 5 46 0.90 (0.70 to 1.00)
HPV 58 1 1 5 45 0.81 (0.56 to 1.00)
HPV 59 2 0 1 49 0.49 (−0.12 to 1.00)
HPV 68 0 0 6 46 1.00 (1.00 to 1.00)
Any pHR 3 0 20 29 0.88 (0.75 to 100)
HPV 66 3 0 3 46 0.64 (0.27 to 1.00)
HPV 26 0 0 2 50 1.00 (1.00 to 1.00)
HPV 53 3 0 4 45 0.70 (0.38 to 1.00)
HPV 70 0 0 5 47 1.00 (1.00 to 1.00)
HPV 73 2 0 2 48 0.65 (0.20 to 1.00)
HPV 82 1 0 6 45 0.91 (0.74 to 1.00)
Any LR 12 4 12 24 0.37 (0.12 to 0.61)
HPV 6 1 0 2 49 0.79 (0.39 to 1.00)
HPV 11 0 0 2 50 1.00 (1.00 to 1.00)
HPV 40 7 0 1 44 0.20 (−0.13 to 0.52)
HPV 42 0 0 0 52 1.00 (1.00 to 1.00)
HPV 43 1 1 1 49 0.48 (−0.13 to 1.00)
HPV 44 3 0 2 47 0.55 (0.10 to 0.99)
HPV 54 3 1 1 47 0.30 (−0.20 to 1.00)
HPV 61 3 1 4 44 0.63 (0.29 to 0.96)
HPV 81 3 1 2 46 0.46 (0.02 to 0.90)
Any UR 8 1 8 24 0.54 (0.29 to 0.79)
HPV 62 6 0 4 42 0.52 (0.20 to 0.84)
HPV 67 0 1 4 47 0.88 (0.64 to 1.00)
HPV 83 2 0 0 50 0.00 (0.00 to 0.00)
HPV 89 1 0 2 49 0.79 (0.39 to 1.00)
CI, confidence interval; CS, ThinPrep cervical smear; FSW, female sex worker; HPV, human papillomavirus; HR, high-risk; LR, low-risk; pHR, probably high-risk; 
UR, unknown risk; VA, vaginal Abbott swab.
Paired analysis revealed that HPV positivity was often detected exclusively in VA samples, 
especially for non-HR genotypes (Fig. 2). In the light of HPV screening, however, equivalent 
detection of (p)HR-HPV genotypes is the key issue. When considering the HR and pHR groups 
combined, there was complete agreement between VA and CS. In contrast, for the non-HR 
groups combined, a substantial number of samples (36% [13/36]) was positive only in VA.
The mean number of genotypes identified in VA samples (mean=3.5; 95% confidence interval 
[CI]=2.8–4.2) was significantly higher than in CS samples (mean=2.6; 95% CI=2.1–3.0) 
(p=0.001) (Fig. 3). This difference was noticeable both in the HR-/pHR-HPV subgroup (2.4 in 
VA vs. 2.0 in CS [p=0.012]) and the LR-/UR-HPV subgroup (1.1 in VS vs. 0.6 in CS [p<0.001]). 
The most frequently encountered HR-HPV genotypes were HPV 16, 31, 51, and 52 (Table 1).
The 14 HR-HPV genotypes included in the Abbott HR-HPV assay are also covered by the 
INNO-LiPa assay, enabling comparison of the results of both assays for those genotypes. As 
we included paired samples (VA and CS) from 52 FSW, the Abbott and INNO-LiPa results 
of 104 samples could be compared. Overall, 11/104 analyses (11%) from 8 different FSWs 
showed discordant results for at least one of these 14 genotypes, in favor of INNO-LiPa: 7 VA 
samples and 4 CS samples showed the presence of at least one genotype with INNO-LiPa that 
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p=0.039
Any HR-HPV Any pHR-HPV Any LR-HPV Any UR-HPV* Any HR
/pHR-HPV
Any LR/UR-HPV*
VA+/CS+ VA+ CS+
Fig. 2. Paired analysis of HPV positivity for each risk group in VA and CS from 52 FSWs. 
CS, ThinPrep cervical smear; FSW, female sex worker; HPV, human papillomavirus; HR, high-risk; LR, low-risk; 
pHR, probably high-risk; UR, unknown risk; VA, vaginal Abbott swab. 
*Significant difference between VA and CS (p=0.039).
0%
10%
20%
30%
0 types 1 types 2 types 3 types 4 types 5 types 6 types >6 types
VA CS
Fig. 3. Number of HPV genotypes identified in paired VA and CS samples collected from 52 FSWs. 
CS, ThinPrep cervical smear; FSW, female sex worker; HPV, human papillomavirus; VA, vaginal Abbott swab.
was not detected with Abbott. The Abbott amplification curves of each discordant sample 
were examined, in order to detect any weak amplification signal below the assay cutoff. 
In summary, HPV 66 was missed 4 times (twice weak amplification signal and twice not 
detected); HPV 68 was missed 3 times (each time not detected); HPV 52 was missed twice (1 
weak amplification signal and once not detected); HPV 58 was missed twice (each time not 
detected) and HPV 31, 51, and 18 were missed once (weak amplification signal). It should 
be noticed, however, that only 2/8 FSWs with discordant results had HSIL cervical cytology. 
Moreover, both FSW were positive for HPV 16 both with Abbott as with INNO-LiPa, reflecting 
the dubious relevance of the discordant results for the other HR-HPV genotypes.
Besides the 14 mutual HR-HPV genotypes, the INNO-LiPa assay detects 4 additional (p)HR-
HPV genotypes: HPV 26, 53, 73, and 82. One should be aware that these additional genotypes 
are usually not included in assays currently approved for primary HPV testing [8]. Therefore, 
theoretically, HSIL cases with isolated positivity for one of these (p)HR-HPV genotypes could 
be missed. We explored the occurrence of such events in our dataset and found 23 FSWs to be 
positive for at least one of these genotypes. However, all but one of these FSW showed positivity 
for one of the 14 HR-HPV genotypes that are included in the Abbott assay as well. Only 1 FSW 
was positive for HPV 73 and negative for each of the 14 mutual HR-HPV genotypes. In case of 
primary HPV testing with the Abbott HR-HPV assay, this FSW would have been missed.
DISCUSSION
Within the studied population, we found a prevalence rate for HR-HPV of 51%, taking both 
positivity on vaginal swabs and cervical smears into account. When only considering the 
results on cervical smear, the gold standard, the prevalence falls back to 42%. This is lower 
than the number reported in a study conducted in the same Pasop vzw population between 
1992 and 2001 (56%), and similar to other studies conducted worldwide in FSW (mean=41%; 
range=2%–100%) [9-16]. The prevalence rate in the general population is markedly lower, as 
reported in literature and estimated by the Centers for Disease Control and Prevention (CDC) 
(mean=24%; range=22%–27%) [9,17,18].
The majority of FSWs (82%) showed NILM or ASC-US on cervical cytology, often (66%) with 
a negative result for HR-HPV. In contrast, the subgroup of FSW with LSIL or HSIL abnormity 
on cervical cytology (18% of FSW) was predominantly positive for HR-HPV (80%). Given 
the choice of the studied population, one could presume that a positive HPV result following 
recent sexual activity could be derived from the male partner, even when condoms are used 
[19]. Although a small study found no effect on HPV detection when vaginal intercourse 
occurred within 48 hours of self-sampling, further study is needed to evaluate the effect of 
vaginal intercourse on HPV screening and cervical cytology [20].
Cervical screening programs have not achieved adequate coverage of the populations at risk. In 
Belgium, for instance, the current screening coverage is only 59% in women 25 to 64 years old 
[21]. Even when screening is readily available, ignorance and fear of pelvic examination may 
create barriers. As multiple screening strategies include (primary) HPV testing, self-collection 
of vaginal samples instead of physician-collected cervical smears could increase the accessibility 
of screening. Indeed, multiple studies have suggested that vaginal self-sampling is an effective 
way to collect exfoliated cell specimens from the vaginal tract and cervix and is better accepted 
[3,22]. However, little is known on the clinical validity of (self-collected) vaginal samples, as 
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vulvovaginal contamination could lead to the detection of more and other genotypes compared 
to the physician-collected cervical smears. Besides, the performance of HPV testing on self-
collected samples is debatable. Arbyn et al. [23] conducted a meta-analysis to investigate 
the clinical accuracy of HPV testing on a self-sample in comparison with samples taken by a 
clinician in women attending cervical cancer screening. As both the pooled sensitivity and 
specificity were lower in self-samples vs. clinician-taken samples, they recommend sampling 
by a clinician to be retained in screening programs using signal-based assays. However, they 
suggest the use of HPV testing on a self-sample as an additional strategy to reach women not 
participating in the regular screening program. In studies comparing self-collected vaginal 
swabs with physician-collected cervical smears, vaginal swabs were more often positive and 
contained a greater number of genotypes compared to physician-collected samples [24,25]. 
Our study confirms these findings. Complete agreement between paired vaginal samples and 
cervical smears was far from achieved and (mainly non-HR) HPV positivity was often detected 
exclusively in vaginal samples. Despite these divergences, most importantly, the sensitivity of 
vaginal swabs for the detection of HR-HPV and pHR-HPV was 100%, enabling vaginal swabs to 
serve as an acceptable sample for primary HPV testing. The suboptimal specificity (70% for HR-
HPV and 91% for pHR-HPV), however, suggests the need of additional testing in case of HPV 
positivity, e.g., cervical cytology. Internal preliminary research (data not published) revealed 
that FSW with HR-HPV detected in the vaginal region only are likely to have normal cervical 
cytology results. As epidemiological data show that HPV infection is common and transient 
in 90% of cases within two years, with only a few individuals developing persistent infections, 
isolated HPV positivity in the vaginal region in the absence of abnormal cervical cytology 
should be interpreted carefully [26,27]. Indeed, HPV detected in vaginal swabs could represent 
freshly infected vaginal cells, whether or not as a prelude of later cervical infection, rather than 
exfoliation from infected cervical cells. Besides, one should take into account that the cancer-
causing effects of HPV are not limited to the cervix, but also vulvar and vaginal cancers are 
attributable to HPV [1].
We evaluated the concordance between Abbott HR-HPV RealTime PCR and INNO-LiPA 
HPV Genotyping Extra II, for the 14 HPV genotypes common to both assays in both vaginal 
swabs and cervical smears. Detection of most analyses was similar in 89% (83/104) of cases. 
In case of discordance, INNO-LiPa detected more genotypes than Abbott, suggesting an 
increased sensitivity of HPV DNA detection. However, the clinical relevance of these findings 
is debatable, as only 2 out of 8 FSWs with discordant results had HSIL cervical cytology and 
both of them were positive for HPV 16 with both assays as well. In addition, it should be 
noticed that the Abbott software uses clinical cutoffs which apply only to cervical smears, we 
examined the amplification curves of each discordant sample, in order to detect any weak 
amplification signal below this assay cutoff. In contrast to our findings, the previous version 
of the INNO-LiPA genotyping assay (INNO-LiPA HPV Genotyping Extra) showed a lower 
sensitivity compared to type-specific multiplex HPV PCR assays [28].
Besides the 14 HR-HPV genotypes included in both assays, INNO-LiPA detects 5 additional 
(p)HR-HPV genotypes. As these genotypes are not included in the assays currently approved 
for primary HPV testing, cases with isolated positivity for one of these genotypes could be 
missed. In our study, however, the only FSW who met these criteria had LSIL cervical cytology, 
reflecting the limited relevance of additional testing for these (p)HR-HPV genotypes.
The main purpose of our study was to explore the use of vaginal swabs instead of cervical 
smears for (primary) HPV testing. Though close consideration was given to the order in 
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which samples were taken, the order was not altered during the study, whereby potential 
influences on the results cannot be fully excluded. However, it has been proven that the 
sampling order, the frequency of sampling and the interval between sampling do not 
influence HPV detection [24]. A second issue might be that vaginal swabs are not validated 
by Abbott for HPV testing, as clinical cutoffs derived from studies using cervical smears 
are applied when interpreting the results. We responded to this concern by manually 
inspecting the amplification curves in case of discordant results. Next, as FSW were included 
chronologically, follow up samples were only available by coincidence at varying time 
intervals. The lack of consistent follow up samples hampers unambiguous interpretation of 
the predominance of HPV positivity in vaginal swabs. At the moment, we cannot confirm 
that this positivity represents local infection or exfoliation of cervical cells. In analogy with 
current cervical cancer screening programs, we used the data of cervical cytology to give 
direction to cervical pathology instead of sampling for histology. However, this approach 
provides less accurate information on the true cervical pathology. Finally, as we studied a 
population of FSW, which are at higher risk for STI than the overall population, caution is to 
be made when generalizing our results to lower prevalence populations.
In conclusion, our study shows that vaginal swabs are equivalent to cervical smears for the 
detection of (p)HR-HPV in a population of FSW. As the vast majority of women might favor self-
sampling over physician-sampling, vaginal sampling offers an opportunity to boost screening 
coverage. However, the clinical accuracy of HPV on self-collected samples needs to be further 
documented in larger clinical trials, following females over a long period. In the meantime, 
cytological data are unbearable to interpret the clinical value of (probable) HR-HPV positivity.
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